



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/29</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/12561</b> <b>(43) International Publication Date:</b> 18 March 1999 (18.03.99)
<b>(21) International Application Number:</b> PCT/EP98/05550 <b>(22) International Filing Date:</b> 2 September 1998 (02.09.98) <b>(30) Priority Data:</b> 60/058,324 9 September 1997 (09.09.97) US <b>(71) Applicant:</b> F. HOFFMAN-LA ROCHE AG [CH/CH]; 124 Grenzacherstrasse, CH-4070 Basel (CH). <b>(72) Inventor:</b> VICKERY, Brian, Henry; 27977 Via Ventana, Los Altos Hills, CA 94022 (US). <b>(74) Agent:</b> BRAUN, Axel; 124 Grenzacherstrasse, CH-4070 Basel (CH).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> FRACTURE HEALING USING PTHrP ANALOGS  <b>(57) Abstract</b>  The present invention provides methods of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, wherein amino acid residues 22-31 form an amphipathic $\alpha$ -helix or the use of such a polypeptide for the preparation of a medicament for the treatment of bone healing and fracture repair.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## Fracture healing using Pthrp Analogs

Approximately 8-10 million bone fractures are reported annually in the United States with more than 1 million of these requiring hospitalization. The estimated annual costs of treating these fractures exceeds 20 billion dollars. While this is already significant, these numbers are expected to increase due to the aging of the general population. Even though several therapies are indicated for preventing the bone loss associated with aging, there are fewer therapies indicated for treatment once a fracture has occurred. Most of these require local administration which is undesirable due to the complexity of delivery and poor patient compliance. Therefore, it would be desirable to have additional methods of facilitating bone healing and fracture repair.

It has recently been reported that intermittent treatment with parathyroid hormone (PTH) improves fracture healing in ovariectomized rats, indicating that PTH treatment may be potentially useful in treating postmenopausal osteoporotic fractures. (H.W. Kim *et al.*; Transactions of the 43rd Annual Meeting of the Orthopaedic Research Society, Vol. 22, Section 1, Abstract 181-31, February 9-13, 1997; H.W. Kim *et al.*; Journal of Bone and Mineral Research, Vol. 11, Supplement 1, page S152, Abstract P248 (August 1996)). Other investigators have reported that implantation of a gene activated matrix expressing bone morphogenetic protein-4 and/or a fragment of PTH (amino acids 1-34) into the segmented defect rat fracture model causes formation of new bone which bridges the gap more rapidly than an untreated control. (Jianming Fang *et al.*; Proc. Natl. Acad. Sci. (USA), Vol. 93:5753-5758 (June 1996)). Various PTH analogs have also been reported to be useful for treatment of osteoporosis (U.S. Patent Nos. 5,556,940 and 5,559,792). Other methods of fracture healing include the use of human platelet factor 4 (U.S. Patent No. 5,622,935), benzothiophenes (U.S. Patent No. 5,502,074) and 24,25(OH)<sub>2</sub> vitamin D<sub>3</sub> (U.S. Patent No. 5,069,905).

PTH related peptide (PTHrP), previously known as the factor responsible for humoral hypercalcemia of malignancy, is a peptide of 138-174 amino acids (depending on alternative splicing) which binds to the PTH/PTHrP receptor. The N-terminal 34 amino acid sequence of PTHrP is of limited sequence

homology to that of PTH, but in certain cases shows similar activity to PTH. However, PTHrP is generally less potent and less bone anabolic than PTH and has not been associated with fracture healing. The sequence of hPTHrP (1-34) is as follows:

5           Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile  
                   1                   5                   10                   15  
           Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu  
                                   20                   25                   30  
                                   Ile His Thr Ala (SEQ ID NO:1).

10           Several truncated homologs and analogs of PTHrP have been reported. Analogs in which amino acid residues 22-31 of PTHrP(1-34) are replaced by an amphipathic  $\alpha$ -helix (U.S. Patent No. 5,589,452 and WO 97/07815) and related derivatives have been described as useful for treating osteoporosis. (B. H. Vickery *et al.* J.Bone & Mineral Research, **11**(12):1943-1951 (1996); D. Leaffer  
 15 *et al.* Endocrinology, **136**(8):3624-3631 (1995)). Monocyclic and bicyclic analogs of PTHrP (1-34) and PTHrP(7-34) were shown to bind strongly to the PTH receptor and stimulate (or antagonise) PTH-stimulated adenylyl cyclase activity in osteoblast-like cells. (Michael Chorev *et al.* Biochemistry, **36**:3293-3299 (1997), and WO 96/40193).

20           In one aspect, this invention provides methods of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, wherein amino acid residues 22-31 form an amphipathic  $\alpha$ -helix, preferably composed of hydrophilic amino acids (Haa)  
 25 and lipophilic amino acids (Laa) ordered in the sequence:

Haa (Laa Laa Haa Laa)<sub>2</sub> Laa;

or the use of such compounds for the preparation of a medicament for the treatment of such disorders.

30           When illustrative embodiments of this amphipathic helix are inserted into the PTHrP sequence, particularly into N-terminal truncates of human PTHrP (residues 1-32 through 1-38), the resulting polypeptides are effective in bone healing and fracture repair. Systemic administration is a preferred mode of delivery.

A brief description of the drawings is given below:

Figure 1 shows the weekly radiographic density of a segmented bone defect in the rat fracture model over the course of five weeks of treatment with PTHrP analogs B or C relative to control. It shows that after four weeks, bone growth in the defects of animals treated with the PTHrP analogs was greater than in the control animals. PTHrP analogs B and C are  $(\text{MAP}_{1-10})^{22-31}\text{Ala}^{19}\text{hPTHrP}(1-34)\text{NH}_2$  and  $(\text{MAP}_{1-10})^{22-31}\text{His}^{26}\text{hPTHrP}(1-34)\text{NH}_2$  respectively.

Figure 2 shows the radiographic density ratio of the segmented bone to the contralateral femur (control) in the segmented defect rat fracture model after six weeks of treatment with control or PTHrP analogs B or C. Rats treated with PTHrP analogs B and C had an increased bone density relative to control treated rats.

Figure 3 shows high resolution radiographs of bone defects in the segmented defect rat fracture model of rats after treatment for six weeks with either control (3A) or PTHrP analog C (3B). The radiograph demonstrates that the control defect remains non-united whereas the defect treated with PTHrP analog C has healed.

Figures 4A and 4B show the healing of an intramembraneous bone defect in rabbits after treatment with PTHrP analog D,  $(\text{MAP}_{1-10})^{22-31}\text{hPTHrP}(1-34)\text{NH}_2$  at two different doses.

Figure 5 shows the union rate achieved in the corticosteroid induced delayed healing fracture model with PTHrP analog D,  $(\text{MAP}_{1-10})^{22-31}\text{hPTHrP}(1-34)\text{NH}_2$ .

In the following a more detailed description of the invention is given.

The one- and three-letter abbreviations for the various common nucleotide bases and amino acids are as recommended in Pure Appl. Chem. **31**: 639-645 (1972) and **40**: 277-290 (1974). The abbreviations represent L amino acids unless otherwise designated as D or D,L. Certain amino acids, both natural and non natural, are achiral, e.g. glycine. All peptide sequences are presented with the N terminal amino acid on the left and the C terminal amino acid on the right.

It will be recognized that both natural and unnatural amino acids may be present in the PTHrP analogs used in this invention. Examples of unnatural amino acids and their abbreviations include, homoserine (hSer), homoserine lactone (hSerlac), homocysteine (Hcy), homoarginine (hArg), homocitrulline (Hci), penicillamine (Pen),  $\text{N}\alpha$ -methylarginine (N-MeArg), norleucine (Nle),

norvaline (Nval), norisoleucine (Nile), N-methylisoleucine (N-Melle), phenylglycine (PhG), t-butylglycine (Tle), hydroxyproline (Hyp), 3,4-dehydroproline ( $\Delta$ -Pro), pyroglutamine (Pyr, Glp), ornithine (Orn), , 1-aminoisobutyric acid (1-Aib), 2-aminoisobutyric acid (2-Aib), 2-aminobutyric acid (2-Abu), 4-aminobutyric acid (4-Abu), 2,4-diaminobutyric acid (A2bu),  $\alpha$ -aminosuberic acid (Asu), albizzin (Abz),  $\beta$ -cyclohexylalanine (Cha), 3-(1-naphthyl)alanine (1-Nal), 3-(2-naphthyl)alanine (2-Nal), citrulline (Cit).  
 5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55  
 60  
 65  
 70  
 75  
 80  
 85  
 90  
 95  
 100  
 105  
 110  
 115  
 120  
 125  
 130  
 135  
 140  
 145  
 150  
 155  
 160  
 165  
 170  
 175  
 180  
 185  
 190  
 195  
 200  
 205  
 210  
 215  
 220  
 225  
 230  
 235  
 240  
 245  
 250  
 255  
 260  
 265  
 270  
 275  
 280  
 285  
 290  
 295  
 300  
 305  
 310  
 315  
 320  
 325  
 330  
 335  
 340  
 345  
 350  
 355  
 360  
 365  
 370  
 375  
 380  
 385  
 390  
 395  
 400  
 405  
 410  
 415  
 420  
 425  
 430  
 435  
 440  
 445  
 450  
 455  
 460  
 465  
 470  
 475  
 480  
 485  
 490  
 495  
 500  
 505  
 510  
 515  
 520  
 525  
 530  
 535  
 540  
 545  
 550  
 555  
 560  
 565  
 570  
 575  
 580  
 585  
 590  
 595  
 600  
 605  
 610  
 615  
 620  
 625  
 630  
 635  
 640  
 645  
 650  
 655  
 660  
 665  
 670  
 675  
 680  
 685  
 690  
 695  
 700  
 705  
 710  
 715  
 720  
 725  
 730  
 735  
 740  
 745  
 750  
 755  
 760  
 765  
 770  
 775  
 780  
 785  
 790  
 795  
 800  
 805  
 810  
 815  
 820  
 825  
 830  
 835  
 840  
 845  
 850  
 855  
 860  
 865  
 870  
 875  
 880  
 885  
 890  
 895  
 900  
 905  
 910  
 915  
 920  
 925  
 930  
 935  
 940  
 945  
 950  
 955  
 960  
 965  
 970  
 975  
 980  
 985  
 990  
 995  
 1000  
 1005  
 1010  
 1015  
 1020  
 1025  
 1030  
 1035  
 1040  
 1045  
 1050  
 1055  
 1060  
 1065  
 1070  
 1075  
 1080  
 1085  
 1090  
 1095  
 1100  
 1105  
 1110  
 1115  
 1120  
 1125  
 1130  
 1135  
 1140  
 1145  
 1150  
 1155  
 1160  
 1165  
 1170  
 1175  
 1180  
 1185  
 1190  
 1195  
 1200  
 1205  
 1210  
 1215  
 1220  
 1225  
 1230  
 1235  
 1240  
 1245  
 1250  
 1255  
 1260  
 1265  
 1270  
 1275  
 1280  
 1285  
 1290  
 1295  
 1300  
 1305  
 1310  
 1315  
 1320  
 1325  
 1330  
 1335  
 1340  
 1345  
 1350  
 1355  
 1360  
 1365  
 1370  
 1375  
 1380  
 1385  
 1390  
 1395  
 1400  
 1405  
 1410  
 1415  
 1420  
 1425  
 1430  
 1435  
 1440  
 1445  
 1450  
 1455  
 1460  
 1465  
 1470  
 1475  
 1480  
 1485  
 1490  
 1495  
 1500  
 1505  
 1510  
 1515  
 1520  
 1525  
 1530  
 1535  
 1540  
 1545  
 1550  
 1555  
 1560  
 1565  
 1570  
 1575  
 1580  
 1585  
 1590  
 1595  
 1600  
 1605  
 1610  
 1615  
 1620  
 1625  
 1630  
 1635  
 1640  
 1645  
 1650  
 1655  
 1660  
 1665  
 1670  
 1675  
 1680  
 1685  
 1690  
 1695  
 1700  
 1705  
 1710  
 1715  
 1720  
 1725  
 1730  
 1735  
 1740  
 1745  
 1750  
 1755  
 1760  
 1765  
 1770  
 1775  
 1780  
 1785  
 1790  
 1795  
 1800  
 1805  
 1810  
 1815  
 1820  
 1825  
 1830  
 1835  
 1840  
 1845  
 1850  
 1855  
 1860  
 1865  
 1870  
 1875  
 1880  
 1885  
 1890  
 1895  
 1900  
 1905  
 1910  
 1915  
 1920  
 1925  
 1930  
 1935  
 1940  
 1945  
 1950  
 1955  
 1960  
 1965  
 1970  
 1975  
 1980  
 1985  
 1990  
 1995  
 2000  
 2005  
 2010  
 2015  
 2020  
 2025  
 2030  
 2035  
 2040  
 2045  
 2050  
 2055  
 2060  
 2065  
 2070  
 2075  
 2080  
 2085  
 2090  
 2095  
 2100  
 2105  
 2110  
 2115  
 2120  
 2125  
 2130  
 2135  
 2140  
 2145  
 2150  
 2155  
 2160  
 2165  
 2170  
 2175  
 2180  
 2185  
 2190  
 2195  
 2200  
 2205  
 2210  
 2215  
 2220  
 2225  
 2230  
 2235  
 2240  
 2245  
 2250  
 2255  
 2260  
 2265  
 2270  
 2275  
 2280  
 2285  
 2290  
 2295  
 2300  
 2305  
 2310  
 2315  
 2320  
 2325  
 2330  
 2335  
 2340  
 2345  
 2350  
 2355  
 2360  
 2365  
 2370  
 2375  
 2380  
 2385  
 2390  
 2395  
 2400  
 2405  
 2410  
 2415  
 2420  
 2425  
 2430  
 2435  
 2440  
 2445  
 2450  
 2455  
 2460  
 2465  
 2470  
 2475  
 2480  
 2485  
 2490  
 2495  
 2500  
 2505  
 2510  
 2515  
 2520  
 2525  
 2530  
 2535  
 2540  
 2545  
 2550  
 2555  
 2560  
 2565  
 2570  
 2575  
 2580  
 2585  
 2590  
 2595  
 2600  
 2605  
 2610  
 2615  
 2620  
 2625  
 2630  
 2635  
 2640  
 2645  
 2650  
 2655  
 2660  
 2665  
 2670  
 2675  
 2680  
 2685  
 2690  
 2695  
 2700  
 2705  
 2710  
 2715  
 2720  
 2725  
 2730  
 2735  
 2740  
 2745  
 2750  
 2755  
 2760  
 2765  
 2770  
 2775  
 2780  
 2785  
 2790  
 2795  
 2800  
 2805  
 2810  
 2815  
 2820  
 2825  
 2830  
 2835  
 2840  
 2845  
 2850  
 2855  
 2860  
 2865  
 2870  
 2875  
 2880  
 2885  
 2890  
 2895  
 2900  
 2905  
 2910  
 2915  
 2920  
 2925  
 2930  
 2935  
 2940  
 2945  
 2950  
 2955  
 2960  
 2965  
 2970  
 2975  
 2980  
 2985  
 2990  
 2995  
 3000  
 3005  
 3010  
 3015  
 3020  
 3025  
 3030  
 3035  
 3040  
 3045  
 3050  
 3055  
 3060  
 3065  
 3070  
 3075  
 3080  
 3085  
 3090  
 3095  
 3100  
 3105  
 3110  
 3115  
 3120  
 3125  
 3130  
 3135  
 3140  
 3145  
 3150  
 3155  
 3160  
 3165  
 3170  
 3175  
 3180  
 3185  
 3190  
 3195  
 3200  
 3205  
 3210  
 3215  
 3220  
 3225  
 3230  
 3235  
 3240  
 3245  
 3250  
 3255  
 3260  
 3265  
 3270  
 3275  
 3280  
 3285  
 3290  
 3295  
 3300  
 3305  
 3310  
 3315  
 3320  
 3325  
 3330  
 3335  
 3340  
 3345  
 3350  
 3355  
 3360  
 3365  
 3370  
 3375  
 3380  
 3385  
 3390  
 3395  
 3400  
 3405  
 3410  
 3415  
 3420  
 3425  
 3430  
 3435  
 3440  
 3445  
 3450  
 3455  
 3460  
 3465  
 3470  
 3475  
 3480  
 3485  
 3490  
 3495  
 3500  
 3505  
 3510  
 3515  
 3520  
 3525  
 3530  
 3535  
 3540  
 3545  
 3550  
 3555  
 3560  
 3565  
 3570  
 3575  
 3580  
 3585  
 3590  
 3595  
 3600  
 3605  
 3610  
 3615  
 3620  
 3625  
 3630  
 3635  
 3640  
 3645  
 3650  
 3655  
 3660  
 3665  
 3670  
 3675  
 3680  
 3685  
 3690  
 3695  
 3700  
 3705  
 3710  
 3715  
 3720  
 3725  
 3730  
 3735  
 3740  
 3745  
 3750  
 3755  
 3760  
 3765  
 3770  
 3775  
 3780  
 3785  
 3790  
 3795  
 3800  
 3805  
 3810  
 3815  
 3820  
 3825  
 3830  
 3835  
 3840  
 3845  
 3850  
 3855  
 3860  
 3865  
 3870  
 3875  
 3880  
 3885  
 3890  
 3895  
 3900  
 3905  
 3910  
 3915  
 3920  
 3925  
 3930  
 3935  
 3940  
 3945  
 3950  
 3955  
 3960  
 3965  
 3970  
 3975  
 3980  
 3985  
 3990  
 3995  
 4000  
 4005  
 4010  
 4015  
 4020  
 4025  
 4030  
 4035  
 4040  
 4045  
 4050  
 4055  
 4060  
 4065  
 4070  
 4075  
 4080  
 4085  
 4090  
 4095  
 4100  
 4105  
 4110  
 4115  
 4120  
 4125  
 4130  
 4135  
 4140  
 4145  
 4150  
 4155  
 4160  
 4165  
 4170  
 4175  
 4180  
 4185  
 4190  
 4195  
 4200  
 4205  
 4210  
 4215  
 4220  
 4225  
 4230  
 4235  
 4240  
 4245  
 4250  
 4255  
 4260  
 4265  
 4270  
 4275  
 4280  
 4285  
 4290  
 4295  
 4300  
 4305  
 4310  
 4315  
 4320  
 4325  
 4330  
 4335  
 4340  
 4345  
 4350  
 4355  
 4360  
 4365  
 4370  
 4375  
 4380  
 4385  
 4390  
 4395  
 4400  
 4405  
 4410  
 4415  
 4420  
 4425  
 4430  
 4435  
 4440  
 4445  
 4450  
 4455  
 4460  
 4465  
 4470  
 4475  
 4480  
 4485  
 4490  
 4495  
 4500  
 4505  
 4510  
 4515  
 4520  
 4525  
 4530  
 4535  
 4540  
 4545  
 4550  
 4555  
 4560  
 4565  
 4570  
 4575  
 4580  
 4585  
 4590  
 4595  
 4600  
 4605  
 4610  
 4615  
 4620  
 4625  
 4630  
 4635  
 4640  
 4645  
 4650  
 4655  
 4660  
 4665  
 4670  
 4675  
 4680  
 4685  
 4690  
 4695  
 4700  
 4705  
 4710  
 4715  
 4720  
 4725  
 4730  
 4735  
 4740  
 4745  
 4750  
 4755  
 4760  
 4765  
 4770  
 4775  
 4780  
 4785  
 4790  
 4795  
 4800  
 4805  
 4810  
 4815  
 4820  
 4825  
 4830  
 4835  
 4840  
 4845  
 4850  
 4855  
 4860  
 4865  
 4870  
 4875  
 4880  
 4885  
 4890  
 4895  
 4900  
 4905  
 4910  
 4915  
 4920  
 4925  
 4930  
 4935  
 4940  
 4945  
 4950  
 4955  
 4960  
 4965  
 4970  
 4975  
 4980  
 4985  
 4990  
 4995  
 5000  
 5005  
 5010  
 5015  
 5020  
 5025  
 5030  
 5035  
 5040  
 5045  
 5050  
 5055  
 5060  
 5065  
 5070  
 5075  
 5080  
 5085  
 5090  
 5095  
 5100  
 5105  
 5110  
 5115  
 5120  
 5125  
 5130  
 5135  
 5140  
 5145  
 5150  
 5155  
 5160  
 5165  
 5170  
 5175  
 5180  
 5185  
 5190  
 5195  
 5200  
 5205  
 5210  
 5215  
 5220  
 5225  
 5230  
 5235  
 5240  
 5245  
 5250  
 5255  
 5260  
 5265  
 5270  
 5275  
 5280  
 5285  
 5290  
 5295  
 5300  
 5305  
 5310  
 5315  
 5320  
 5325  
 5330  
 5335  
 5340  
 5345  
 5350  
 5355  
 5360  
 5365  
 5370  
 5375  
 5380  
 5385  
 5390  
 5395  
 5400  
 5405  
 5410  
 5415  
 5420  
 5425  
 5430  
 5435  
 5440  
 5445  
 5450  
 5455  
 5460  
 5465  
 5470  
 5475  
 5480  
 5485  
 5490  
 5495  
 5500  
 5505  
 5510  
 5515  
 5520  
 5525  
 5530  
 5535  
 5540  
 5545  
 5550  
 5555  
 5560  
 5565  
 5570  
 5575  
 5580  
 5585  
 5590  
 5595  
 5600  
 5605  
 5610  
 5615  
 5620  
 5625  
 5630  
 5635  
 5640  
 5645  
 5650  
 5655  
 5660  
 5665  
 5670  
 5675  
 5680  
 5685  
 5690  
 5695  
 5700  
 5705  
 5710  
 5715  
 5720  
 5725  
 5730  
 5735  
 5740  
 5745  
 5750  
 5755  
 5760  
 5765  
 5770  
 5775  
 5780  
 5785  
 5790  
 5795  
 5800  
 5805  
 5810  
 5815  
 5820  
 5825  
 5830  
 5835  
 5840  
 5845  
 5850  
 5855  
 5860  
 5865  
 5870  
 5875  
 5880  
 5885  
 5890  
 5895  
 5900  
 5905  
 5910  
 5915  
 5920  
 5925  
 5930  
 5935  
 5940  
 5945  
 5950  
 5955  
 5960  
 5965  
 5970  
 5975  
 5980  
 5985  
 5990  
 5995  
 6000  
 6005  
 6010  
 6015  
 6020  
 6025  
 6030  
 6035  
 6040  
 6045  
 6050  
 6055  
 6060  
 6065  
 6070  
 6075  
 6080  
 6085  
 6090  
 6095  
 6100  
 6105  
 6110  
 6115  
 6120  
 6125  
 6130  
 6135  
 6140  
 6145  
 6150  
 6155  
 6160  
 6165  
 6170  
 6175  
 6180  
 6185  
 6190  
 6195  
 6200  
 6205  
 6210  
 6215  
 6220  
 6225  
 6230  
 6235  
 6240  
 6245  
 6250  
 6255  
 6260  
 6265  
 6270  
 6275  
 6280  
 6285  
 6290  
 6295  
 6300  
 6305  
 6310  
 6315  
 6320  
 6325  
 6330  
 6335  
 6340  
 6345  
 6350  
 6355  
 6360  
 6365  
 6370  
 6375  
 6380  
 6385  
 6390  
 6395  
 6400  
 6405  
 6410  
 6415  
 6420  
 6425  
 6430  
 6435  
 6440  
 6445  
 6450  
 6455  
 6460  
 6465  
 6470  
 6475  
 6480  
 6485  
 6490  
 6495  
 6500  
 6505  
 6510  
 6515  
 6520  
 6525  
 6530  
 6535  
 6540  
 6545  
 6550  
 6555  
 6560  
 6565  
 6570  
 6575  
 6580  
 6585  
 6590  
 6595  
 6600  
 6605  
 6610  
 6615  
 6620  
 6625  
 6630  
 6635  
 6640  
 6645  
 6650  
 6655  
 6660  
 6665  
 6670  
 6675  
 6680  
 6685  
 6690  
 6695  
 6700  
 6705  
 6710  
 6715  
 6720  
 6725  
 6730  
 6735  
 6740  
 6745  
 6750  
 6755  
 6760  
 6765  
 6770  
 6775  
 6780  
 6785  
 6

Polypeptides with cyclized links between amino acid residues are denoted with the two linked residues placed within brackets and preceded by a "c." In general, the links between the two residues are formed between the side chain functionalities, typically as amide or ester bonds. Thus (MAP<sub>1-10</sub>)<sup>22</sup>  
5 <sup>31</sup>c[Lys<sup>13</sup>,Asp<sup>17</sup>]hPTHrP(1-34) hSer<sup>34</sup> lactone refers to the 1-34 N-terminal residues of hPTHrP with the segment between residues 22-31 replaced by the MAP sequence, the amino side chain of lysine at position 13 cyclized with the carboxyl side chain of aspartate at position 17 and an additional homoserine at position 34 with a lactone formed between the hydroxyl side chain of the  
10 homoserine and the carboxyl terminus. Similarly, (MAP<sub>1-10</sub>)<sup>22-31</sup> c[Lys<sup>13</sup>,Asp<sup>17</sup>]hPTHrP(1-34) refers to the 1-34 N-terminal residues of hPTHrP with the segment between residues 22-31 replaced by the MAP sequence and the amino side chain of a lysine at position 13 cyclized with the carboxyl side chain of an aspartate at position 17.

15 "Hydrophilic amino acid (Haa)" refers to an amino acid having at least one hydrophilic functional group in addition to those required for peptide bond formation, such as arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and their homologs.

"Lipophilic amino acid (Laa)" refers to an uncharged, aliphatic or  
20 aromatic amino acid, such as isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, valine, and their homologs.

For the purposes of this invention, alanine is classified as "amphiphilic" i.e., capable of acting as either hydrophilic or lipophilic.

A "polypeptide analog of PTHrP" refers to a polypeptide having art-  
25 accepted substitutions, deletions or insertions relative to PTHrP or is substantially homologous to PTHrP such that the analog has a similar physiological activity.

"Physiologically active truncated analog of PTHrP" refers to a polypeptide having a sequence comprising less than the full complement of  
30 amino acids found in PTHrP which, however, elicits a similar physiological response. The truncated PTHrP analogs need not be fully homologous with PTHrP to elicit a similar physiological response. Typically, the truncated analogs will be truncated from the C-terminus and will range from 30 to 40 residues, with PTHrP(1-32), PTHrP(1-34) and PTHrP(1-38) being preferred,  
35 but not exclusive, representatives of this group. Generally, the analogs will

carry conservative substitutions of amino acids according to art-accepted parameters as described below.

The term "substantially homologous," when referring to polypeptides, indicates that the polypeptide in question exhibits at least about 80%  
5 homology, usually about 90% homology, and preferably 95% homology to the referenced polypeptide. Homology for polypeptides is typically measured using sequence analysis software. (See, e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wisconsin 53705 USA).

10 "Amphipathic  $\alpha$ -helix" refers to the secondary structure exhibited by certain polypeptides in which the amino acids assume an  $\alpha$ -helical configuration having opposing polar and nonpolar faces oriented along the long axis of the helix. Amphipathic helical sequences can be designed by those of skill in the art. Particular amphipathic helical sequences suitable for use in  
15 the methods of this invention are described in more detail in, e.g. U.S. Patent No.5,589,452 or WO 97/07815.

The present invention is based upon the finding that certain analogs of PTHrP containing an amphipathic  $\alpha$ -helix at positions 22-31 are effective in bone healing and fracture repair. The amphipathic  $\alpha$ -helix is composed of  
20 hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:

Haa (Laa Laa Haa Laa)<sub>2</sub> Laa

25 When illustrative embodiments of this amphipathic helix are inserted into the PTHrP sequence, particularly into N-terminal truncates of human PTHrP (residues 1-32 through 1-38), the resulting polypeptides are effective in bone healing and fracture repair. Unlike PTH, PTHrP or analogs thereof not having this amphipathic helical segment, the analogs used herein do not cause  
30 hypercalcemia. In addition, these analogs induce a more rapid increase in bone relative to either PTH or PTHrP.

It will be recognized that in addition to containing an amphipathic helix between positions 22 and 31, a variety of substitutions, deletions and insertions of amino acids may be made in the PTHrP sequence outside this  
35 region while still preserving the three dimensional structure of the



polypeptide. Representative variations of the PTH and PTHrP sequence which maintain the physiological activity of the resulting analogs are disclosed in U.S. Patent Nos. 5,599,792, 5,556,940, 5,607,915 and 5,589,452, and WO 91/06564, WO 94/02510, WO 95/11697, WO 96/40193 and WO 5 97/07815. Additional variants which will be expected by one of skill in the art to maintain physiological activity can be made by following art-accepted protein structure modeling techniques. Representative methodologies for deriving such variants are described *inter alia* by I. Ladunga and R.F. Smith, Protein Eng., 3:187-196 (1997) and by M.J. Thompson and R.A. Goldstein, in 10 Proteins, 1:28-37 (1996).

Substitutional variants are those in which at least one amino acid in the native sequence is removed and a different amino acid is put into its place at the same position. The substitutions may be single, where only one amino acid is replaced, or multiple where two or more amino acids are replaced in the 15 same molecule. It is generally expected that any conservative substitutions will be permitted. Thus, an analog corresponding to substituting one hydrophilic amino acid for another hydrophilic amino acid or a hydrophobic amino acid for another hydrophobic amino acid is expected to maintain similar fracture healing properties to its precursor. Substitutions also include PTHrP 20 analogs wherein the C-terminal residue is present as an amide. Additional substitutions may be made based on amino acids being either charged or uncharged. Each of these groups may be further divided into subgroups to further facilitate substitutions.

#### Charged amino acids

25        Acidic residues: aspartic acid, glutamic acid, 2-amino suberic acid

          Basic residues: lysine, arginine, histidine, ornithine

#### Uncharged amino acids

          Hydrophilic residues: serine, threonine, asparagine, glutamine, methionine

30        Aliphatic residues: glycine, alanine, valine, leucine, norleucine, isoleucine

          Nonpolar residues: cysteine, homocysteine, methionine, proline

          Aromatic residues: phenylalanine, tyrosine, tryptophan, histidine

          Alternatively, amino acid substitutions may be based on the principal of bioisosterism. Such bioisosteric substitutions typically minimize any

disruptive conformational effects that random substitution may create. The technique of alanine scanning may be used to identify positions where isosteric substitution is expected to provide variants which retain physiological activity. (See, e.g. K.H. Pearce Jr., M.H. Ultsch, R.F. Kelley, A.M. de Vos and J.A. Wells, *Biochemistry*, **35** (32):10300-10307 (1996) and B. Li, J.Y. Tom, D Oare, R. Yen, W.J. Fairbrother, J.A. Wells and B.C. Cunningham, *Science*, **270**:1657-1660 (1995)). Representative isosteric amino acids are shown in the table below:

Amino acid	Isosteric amino acid
Ala	Ser, Gly
Glu	Gln, Asp
Gln	Asn, Glu
Asp	Asn, Glu
Asn	Ala, Asp
Leu	Met, Ile
Gly	Pro, Ala
Lys	Met, Arg
Ser	Thr, Ala
Val	Ile, Thr
Arg	Lys, Met, Asn
Thr	Ser, Val
Pro	Gly
Ile	Met, Leu, Val
Met	Ile, Leu
Phe	Tyr
Tyr	Phe
Cys	Ser, Ala
Trp	Phe,
His	Asn, Gln

Deletional variants are those with one or more amino acids in the native amino acid sequence removed. Ordinarily, deletional variants will have one or two amino acids deleted in a particular region of the molecule. It is likely that deletions will be made at the ends of the sequence, particularly the carboxy terminus. Thus, though PTHrP(1-34) fragments are preferred, sequences which are further truncated at the carboxyl terminus also have bone healing effects.


Insertional or addition variants are those with the amino acid inserted immediately adjacent to an amino acid at a particular position in the native sequence. Immediately adjacent to an amino acid means connected to either the  $\alpha$ -carboxy or  $\alpha$ -amino group of the amino acid. Addition or insertion variants are also likely to be made at the ends of the sequence, again most likely at the carboxy terminus.

Of the above-listed modifications to the native sequence, substitutions, and carboxy terminus additions and deletions are preferred.


The polypeptide PTHrP analogs that are useful for fracture healing as described herein are generally described, in part, in U.S. Patent No. 5,589,452 and WO 97/07815. Additional analogs include the cyclic analogs of N-terminal hPTHrP(1-32), hPTHrP(1-34) and hPTHrP(1-38) containing a MAP sequence between positions 22 and 31 and optionally having residues at positions 13 and 17 and/or 26 and 30 linked via their side chain functionalities. It will be recognized by one of skill in the art that a variety of substitutions can be made at positions 13 and 17 which would allow cyclization between those two positions.

PTHrP analogs of any mammalian species, e.g., human, bovine, porcine or rabbit may be used in this invention, with human PTHrP being preferred. One of skill in the art will recognize that substitution, deletion and insertion variants of the preferred embodiments enumerated below, according to the art-accepted principles described above, are also within the scope of the invention.

Preferred embodiments include the use of hPTHrP(1-34) analogs with a MAP sequence at positions 22-31, particularly those having a positively charged amino acid at position 26, e.g., lysine or histidine. Specific embodiments within this class are:




Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser IleGln Asp Leu Arg  
 5 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
 NO:3) and




10 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser IleGln Asp Leu Arg  
 Arg Arg Glu Leu Leu Glu His Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
 NO:4).

Other preferred embodiments include the use of hPTHrP(1-34) analogs  
 15 with a MAP sequence at positions 22-31 and additionally containing a mono or  
 bicyclic substructure created by cyclization between the side chain  
 functionalities of the amino acid residues, particularly between residues 13  
 and 17 or between residues 26 and 30. The side chain functionalities are  
 typically amino, hydroxy or carboxyl groups and cyclization occurs via the  
 20 formation of an amide or ester bond. Residues with amino functionality on the  
 side chain include lysine and ornithine. Residues with carboxyl functionality  
 on the side chain include aspartic acid and glutamic acid. Specific  
 embodiments within this class include:



Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr hSerlac (SEQ ID  
 NO:5) and



Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
 5 NO:6).

Other hPTHrP analogs useful in this invention are the N-terminal  
 sequences of between 30 to 50 residues, preferably from 1-32, 1-33, 1-34, 1-35,  
 1-36, 1-37 and 1-38, having the MAP sequence at residues 22-31 and  
 10 optionally having a one or more substitutions at position 5, 13, 17, 19, 26, 30,  
 32 or 34. Specific embodiments within this class include:




Ala Val Ser Glu Ile Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
 15 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
 NO:7),




Ala Val Ser Glu Ile Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Ala  
 20 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
 NO:8),



Ala Val Ser Glu Ile Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Ala  
 25 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Pro NH<sub>2</sub> (SEQ ID NO:9),



Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr D-Orn  
 30 lactam(SEQ ID NO:10),



Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr A2bu lactam(SEQ  
 35 ID NO:11) and

(MAP<sub>1-10</sub>)<sup>22-31</sup>hSer<sup>34</sup>PTHrP(1-34)THIQ NH<sub>2</sub>

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser IleGln Asp Leu Arg  
Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr hSer Thr His Ile  
5 Gln NH<sub>2</sub> (SEQ ID NO 12).

Generally, all polypeptides substantially homologous to the specific  
embodiments disclosed herein are useful for the methods of the invention.  
Ordinarily, the polypeptides used in the present invention will be at least  
10 about 50%, preferably in excess of about 80%, and, more preferably in excess  
of about 90%, most preferably at least about 95% homologous to the specific  
embodiments disclosed herein. The length of polypeptide sequences compared  
for homology will be generally at least about 20 amino acids, usually at least  
about 24 residues, typically at least about 30 residues and preferably between  
15 32 and 40 residues.

The compounds used in the present invention can be made by methods  
described in U.S. Patent No. 5,589,452, and WO 96/40193 and WO 97/07815.  
The compounds are generally made by solid phase synthesis, solution  
synthesis or recombinant methods which proceed via the cloning and  
20 expression of a gene coding for the polypeptide of interest, all known to one of  
skill in the art. Solid phase syntheses are preferred for truncated PTHrP  
analogs of forty or fewer amino acids. Analogs with cyclized side chains are  
generally prepared by assembling the complete protected polypeptide on the  
resin, removing the protecting groups and effecting the cyclization with an  
25 appropriate coupling agent, such as benzotriazol-1-yl-  
oxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) just before  
releasing the polypeptide from the resin.

The methods of treatment disclosed herein may be used for healing of  
bone fractures and osteotomies, including both union and nonunion fractures.  
30 Types of fractures treatable by the methods of this invention include both  
traumatic and osteoporotic fractures, e.g., fractures of the hip, neck of the  
femur, wrist, vertebrae, spine, ribs, sternum, larynx and trachea, radius/ulna,  
tibia, patella, clavicle, pelvis, humerus, lower leg, fingers and toes, face and  
ankle. Other uses include facilitating joint fusions, e.g., fusions of the spine,  
35 ankle and foot, elbow, hip and arthredoses of the hip, knee and shoulder.  
Treatment with the PTHrP analogs as described herein is also indicated in

conjunction with arthroplastic procedures (including revision arthroplasties) of the hip, knee, shoulder/elbow etc. Bone healing may also be enhanced in other surgical settings such as in cranio and maxillofacial surgery, dental surgery and bunionectomy. PTHrP analogs have been shown to accelerate healing  
5 both in endochondral bone (Examples 1 and 2) which proceeds via cartilagenous callous formation, as well as in intramembraneous bone (Example 3) which does not require intermediate callous formation. Healing in intramembraneous bone is particularly useful in cases where fracture healing is delayed, e.g., in diabetics, smokers, geriatrics, anemic patients, and  
10 patients undergoing corticosteroid (particularly chronic glucocorticoids), chronic NSAID or immunosuppressive therapy.

The particular dosage of a PTHrP analog required to facilitate fracture healing according to this invention will depend on the severity of the condition, the route of administration and related factors which will be decided  
15 by the attendant physician. Typically, the dosage will range between about 0.01 and 10  $\mu\text{g/kg}$  body weight per day, preferably from about 0.1 to about 0.5  $\mu\text{g/kg}$  body weight per day. For a 50 kg human subject, the daily dose of active ingredient is from about 0.5 to about 100  $\mu\text{g}$ s, preferably from about 5 to about 10  $\mu\text{g}$ s. This dosage may be delivered in a conventional pharmaceutical  
20 composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results. Dosing will continue for as long as is medically indicated, which depending on the severity of the injury may range from a few weeks to several months.

Unlike most currently available methods of treating fractures, the  
25 PTHrP analogs can be administered systemically. Representative delivery regimens include oral, parenteral (including subcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), transdermal, pulmonary and intranasal. Typical pulmonary and respiratory delivery systems are described in U.S. Patent No. 5,607,915. Nasal delivery of PTHrP analogs is  
30 described in WO 97/07815. Also included in the treatment methods of this invention are systemic administration of PTHrP analogs in conjunction with local treatment of a second bone healing agent. Representative agents for such local administration include the bone morphogenetic proteins (BMP-2 and BMP-7), osteogenic proteins (OP-1), growth factors such as TGF- $\beta$ 1 and  
35 cytokines such as IFN- $\beta$ . Typically these agents are delivered locally in various carriers such as hydroxyapatite and/or calcium carbonate and amylopectin. Systemic administration of PTHrP analogs may also be

combined with alternative methods of fracture healing such as mechanical or biophysical stimulation, e.g., electrical or ultrasound.

PTHrP analogs will typically be administered as pharmaceutical compositions in admixture with a pharmaceutically acceptable, non toxic carrier. As mentioned above, such compositions may be prepared for parenteral (subcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; for intranasal administration, particularly in the form of powders, nasal drops or aerosols; and for rectal or transdermal administration.

Liquid formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. They may employ slightly acidic buffers in pH ranges of about 4 to about 6. Suitable buffers include acetate, ascorbate and citrate at concentrations ranging from about 5 mM to about 50 mM. For oral administration, the formulation can be enhanced by the addition of bile salts or acylcarnitines. Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray. Particular nasal formulations include dry powders suitable for conventional dry powder inhalers (DPI's), liquid solutions or suspensions suitable for nebulization and propellant formulations suitable for use in metered dose inhalers (MDI's). For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.

When formulated for nasal administration, the absorption across the nasal mucous membrane may be enhanced by surfactant acids, such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, glycodeoxycholic acid, cyclodextrins and the like in an amount in the range between about 0.2 and 15 weight percent, preferably between about 0.5 and 4 weight percent, most preferably about 2 weight percent.

Delivery of the compounds of the present invention to the subject over prolonged periods of time, for example, for periods of one week to one year, may be accomplished by a single administration of a controlled release system



containing sufficient active ingredient for the desired release period. Various controlled release systems, such as monolithic or reservoir type microcapsules, depot implants, osmotic pumps, vesicles, micelles, liposomes, transdermal patches, iontophoretic devices and alternative injectable dosage forms may be  
5 utilized for this purpose. Localization at the site to which delivery of the active ingredient is desired is an additional feature of some controlled release devices, which may prove beneficial in the treatment of certain disorders.

EXAMPLESREFERENCE EXAMPLESTablet formulation

The following ingredients are mixed intimately and pressed into single scored  
5 tablets.

Quantity per		
<hr/>		
	Ingredient	tablet, mg
<hr/>		
	compound of this invention	400
	cornstarch	50
10	croscarmellose sodium	25
	lactose	120
	magnesium stearate	5
<hr/>		

Capsule formulation

15 The following ingredients are mixed intimately and loaded into a hard-shell  
gelatin capsule.

Quantity per		
<hr/>		
	Ingredient	capsule, mg
<hr/>		
	compound of this invention	200
20	lactose, spray-dried	148
	magnesium stearate	2
<hr/>		

Suspension formulation

25 The following ingredients are mixed to form a suspension for oral  
administration.

<hr/>		
	Ingredient	Amount
<hr/>		
	compound of this invention	1.0 g
	fumaric acid	0.5 g
	sodium chloride	2.0 g

	methyl paraben	0.15 g
	propyl paraben	0.05 g
	granulated sugar	25.5 g
	sorbitol (70% solution)	12.85 g
5	Veegum K (Vanderbilt Co.)	1.0 g
	flavoring	0.035 ml
	colorings	0.5 mg
	distilled water	q.s. to 100 ml

#### 10 Injectable formulation

The following ingredients are mixed to form an injectable formulation.

	Ingredient	Amount
	compound of this invention	0.2 g
	sodium acetate buffer solution, 0.4 M	2.0 ml
15	HCl (1N) or NaOH (1N)	q.s. to suitable pH
	water (distilled, sterile)	q.s. to 20 ml

#### Nasal formulation

20 The following ingredients are mixed to form a suspension for nasal administration.

	Ingredient	Amount
	PTHrP analog	20 mg/ml
	citric acid	0.2 mg/ml
	sodium citrate	2.6 mg/ml
25	benzalkonium chloride	0.2 mg/ml
	sorbitol	35 mg/ml
	sodium taurocholate or glycocholate	10 mg/ml

## EXAMPLE 1

### Healing of Segmented Fracture Defects with PTHrP Analogs

A modification of the segmental femoral defect rat model was used to demonstrate that PTHrP analogs facilitate bone healing and fracture repair.

5 (T.A. Einhorn *et al.* J. Bone Joint, 66:274-279 (1984)).

Adult male Sprague-Dawley rats weighing about 300 grams were maintained on Laboratory Rodent Diet 5001 (PMI Feeds, St. Louis, MO, USA) and water *ad libitum*. All rats received only water for 12 hours prior to surgery. The animals were anesthetized prior to surgery by IP injection with  
10 ketamine (80 mg/kg) and xylazine (5 mg/kg). A single dose of procaine penicillin was given intramuscularly for prophylaxis against infection.

A lateral approach to the femur was used and a pre-drilled high density polyethylene plate was fixed along the anterior cortex of the femur. During this placement the periosteum of the femur was extensively stripped. A 1 mM  
15 non-critical sized segmental defect was created in the mid portion of the femur shaft. The wound was closed with nylon and chromic sutures.

Postoperatively, the rats were placed in cages with 48 hour post-operative access to food pellets. The animals were monitored at least once daily and animals displaying any signs of illness were examined and given  
20 appropriate therapy, if necessary.

Rats were divided into groups as shown in Table 1 and either a control vehicle (saline) or a PTHrP analog as described herein was administered subcutaneously daily starting on post-operative day 1. Radiographic analyses were performed weekly. Animals were sacrificed at 6 weeks and compared by  
25 radiography.

Sedated rats were placed in the prone position with hindlimbs externally rotated. Serial radiographs of each femur (involved femur and contralateral femur) were taken weekly starting with postoperative week 1. An aluminium phantom device with known density values was included in each radiograph  
30 for calibration. Each radiograph was placed on a translumination board and a picture taken using a DCS 420 digital Kodak camera. These images were then transferred to a Gateway 2000 IBM compatible computer and digitized using image analysis software (Sigma Scan®). An outline of the defect was traced and the average density of the area of the osteotomy measured in treated  
35 animals relative to control animals. Figure 1 shows the increase in bone

density of the osteotomy in treated animals relative to control animals at weekly intervals over the first five weeks of treatment. The average density of the osteotomy was also compared to the average density of the contralateral femur for each weekly reading. Figure 2 shows the radiographic density ratio after six weeks. Comparison of these bone densities showed that the PTHrP analogs had a bone healing effect. After sacrifice (6 weeks), the femurs (experimental and contralateral) were dissected free of soft tissue. Fine grain radiographs were taken of the femurs in the lateral plane. The osteotomy was considered united when there was osseous continuity of the femur across more than 25% of the cross sectional diameter of the defect. Comparison of femurs from treated animals to control animals showed that PTHrP analogs accelerated bone healing and fracture repair. Figure 3 shows a representative radiograph from control (Fig. 1A) and treated (Fig. 1B) animals.

TABLE 1

Group	Compound	Administration	# of Animals	Sacrifice
1	Control	subcutaneous	10	six weeks
2	PTHrP analog B	subcutaneous	10	six weeks
3	PTHrP analog C	subcutaneous	10	six weeks

## EXAMPLE 2

### Bone Healing in the Closed Fracture Defect Model with PTHrP Analogs

The closed fracture model used is the Bonnarens/Einhorn model. (F. Bonnarens and T.A. Einhorn, J. Orthopaedic Research, 2:97-101(1984)). The rats used are as in Example 1. In this model an intramedullary rod is placed retrograde through the distal femur via a medial parapatellar approach. The arthrotomy is then closed with non-resorbable sutures and the intramedullary rod is left in place. A closed transverse fracture is then created by a custom made three point clamping device. The animals are monitored and radiographic analysis is performed as in Example 1. PTHrP analogs accelerated bone healing and fracture repair in this model in treated animals relative to control animals.

### EXAMPLE 3

#### Intramembraneous Bone healing with PTHrP analogs

Rabbits were generally anesthetized and subjected to surgery to create four surface defects, one in each distal femur and one in each proximal tibia. A posterior lateral surgical incision measuring approximately 3 cm. was made to expose the distal lateral femoral condyle. Bone proximal to the knee joint was subperiosteally exposed and a 5 mm drill hole was made, keeping the drill bit cool by constant irrigation. The wound was irrigated with normal saline. Deep tissue was closed with a running 3-0 chronic suture followed by closure of the subcuticular layer with a running 3-0 nylon suture and three to four interrupted stainless steel sutures. A second 3 cm. incision was made over the medial proximal tibia and a 5 mm drill hole was made in the proximal medial tibia. The wound was closed as described previously. The entire procedure was repeated on the contralateral limb.

Stock solutions of PTHrP analog C,  $(\text{MAP}_{1-10})^{22-31}\text{His}^{26}\text{hPTHrP}(1-34)\text{NH}_2$ , and PTHrP analog D,  $(\text{MAP}_{1-10})^{22-31}\text{hPTHrP}(1-34)\text{NH}_2$ , at 800  $\mu\text{g}/\text{ml}$  were prepared by sterile filtration through an 0.22 micron filter and diluted in vehicle to either 20  $\mu\text{g}/\text{ml}$  or 100  $\mu\text{g}/\text{ml}$  just before administration. Vehicle was 30 mg/ml mannitol, 30 mg/ml sucrose, 0.12 mg/ml Tween™ 80, 0.17 mg/ml acetic acid and 2.33 mg/ml sodium acetate trihydrate. PTHrP analogs at either 2  $\mu\text{g}/\text{kg}/\text{day}$  or 10  $\mu\text{g}/\text{kg}/\text{day}$  was administered daily by subcutaneous injection to the surgically treated animals.

Animals were X-rayed weekly for the duration of the study. Densitometric measurements were made using a transilluminating scanner and MetaMorph™ (Universal Imaging, West Chester, PA) software. Radiographs of the lower extremities were performed in internal and external rotation on post-operative day 10 and 21. The animals were sacrificed on post-operative day 30. At the end of the study, animals were euthanized by pentobarbital overdose, tissues were harvested from the left and right femurs and tibias were analyzed by x-ray and histological analysis.

The animals treated with PTHrP analogs C and D showed accelerated intramembraneous bone formation relative to vehicle treated animals. The results for PTHrP analog D are shown in Figures 4A and 4B for the femur and tibia respectively. By day 21 there was no complete healing in either of the femoral or tibial defects in the control treated animals whereas 40% of the of the femoral and tibial defects had healed in the low dose group had healed. At

this same time point, 75% of the tibial defects and 50% of the femoral defects had healed in the high dose group. At sacrifice, radiographic analysis of the specimens confirmed the enhancement of healing in the PTHrP analogue treated animals with over 85% of the high dose tibial defects filled with mineralized tissue while less than 10% of the control tibial defects were filled at sacrifice ( $p < 0.01$ ). Similarly, there was a significant greater percent fill in the PTHrP treated femoral defects than the control treated femoral defects ( $p < 0.01$ ).

#### 10 EXAMPLE 4

##### Enhanced Bone Healing in the Ulnar Osteotomy Model

The purpose of this experiment was to demonstrate that PTHrP analogs can increase the biomechanical strength (Part I) and the kinetics of healing (Part II) in the context of systemic corticosteroid therapy in a rabbit osteotomy model.

Adult male New Zealand White rabbits were used in all experiments. In Part I, ten rabbits were divided into two equal groups and in Part II, twenty rabbits were divided equally. Non critical sized (1 mm) defects were created bilaterally in each rabbit. From two months prior to surgery through six weeks post-operative, all rabbits received daily subcutaneous injections of either prednisone (0.15 mg/kg) in sterile water (experimental group) or sterile saline (control group). Beginning on the first post-operative day, the experimental group were administered daily sub cutaneous infections of PTHrP analog D (0.01 mg/kg), while the control group received injections of normal saline. In Part I, animals were sacrificed at six weeks after creation of the osteotomy. In Part II, animals were sacrificed once radiographic union was reached bilaterally, or in cases of non-union at ten weeks post-operative.

In both sets of experiments, radiological intensity and healing area were analyzed every other week starting two weeks (Part I) or four weeks (Part II) post-operatively. Serial radiographs of the forelimbs were taken and digitized and the bone area was quantified using image analysis software (Sigma Scan Pro). Photodensitometry was used to quantitate the mineral content of the newly formed bone at sites of osteotomy and callus formation. After sacrifice, high resolution faxitron radiographs were taken of both limbs in the

anteroposterior and lateral planes, allowing for analysis of fracture callus dimension and size.

#### Results-(Part I)

Nine out ten PTHrP analog D treated limbs achieved union in six weeks, while only two out of ten achieved union in the vehicle treated controls. These results are shown in Figure 5. At six weeks both anteroposterior and lateral faxitrons revealed significantly greater intensities at the osteotomy sites of treated versus control limbs. Similarly, the intensity of both the proximal and distal ulnar diaphyses was significantly greater in the treated limbs. Laterally, the intensity of the external calluses was also greater in the treated limbs. Biomechanically, the torsional strength of the treated limbs was significantly greater than the vehicle-treated control limbs in terms of both stiffness and maximum torque.

#### Results-(Part II)

At four weeks, the treated limbs demonstrated greater radiographic intensity than the control limbs at the osteotomy site ( $p < 0.01$ ) as well as in the external calluses and ulnar diaphyses. The combined callus areas of the treated limbs was greater ( $p < 0.05$ ) and there was a trend indicating that the osteotomy site was decreasing in size. At six weeks, *in vivo* radiography demonstrated a trend of increased intensity at the osteotomy site of the treated limbs compared to the control limbs, although no differences were observed in callus intensity or area. Radiographically, all the PTHrP analog treated limbs were treated as united and all these animals were sacrificed at six weeks. At eight weeks, four additional limbs (two animals) reached radiographic union and were sacrificed. At ten weeks, the remaining animals were sacrificed, since these limbs showed no radiographic progression towards healing over the preceding four-week period and were thus classified as non-unions. The PTHrP analog treated limbs showed a greater radiographic intensity at the osteotomy site ( $p < 0.05$ ), as well as the ulnar diaphysis and the callus area. The area of the osteotomy was significantly smaller in the PTHrP analog treated limbs than in the vehicle control limbs. Thus in this corticosteroid induced model of delayed healing, PTHrP analog treatment resulted in a complete union rate at six weeks while 75% of untreated limbs showed no tendency to unite at ten weeks.



Claims

1. A method of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, in which amino acid residues 22-31 of said PTHrP analog form an amphipathic  $\alpha$ -helix.
2. Use of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, in which amino acid residues 22-31 of said PTHrP analog form an amphipathic  $\alpha$ -helix for the preparation of a medicament for bone healing and fracture repair.
3. The method of claim 1 or the use of claim 2, wherein the PTHrP analog is administered by nasal delivery.
4. The method of claim 1 or the use of claim 2, further comprising locally administering a second bone healing agent to the fracture.
5. The method of claim 1 or the use of claim 2, wherein the fracture is in intramembraneous bone.
6. The method of claim 1 or the use of claim 2, wherein the PTHrP analog is administered systemically.
7. The method of any one of claims 1 or 3-6 or the use of claim 2 or anyone of claims 3-6, wherein the amphipathic  $\alpha$ -helix is  
Glu Leu Leu Glu Xaa Leu Leu Glu Lys Leu  
wherein Xaa is a positively charged amino acid residue.
8. The method or use of claim 7, wherein Xaa is lysine or histidine.
9. The method or use of claim 8, wherein the PTHrP analog is:  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser IleGln Asp Leu  
Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub>  
(SEQ ID NO:3) or  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser IleGln Asp Leu  
Arg Arg Arg Glu Leu Leu Glu His Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID NO:4).
10. The method or use of claim 7, wherein the PTHrP analog has at least two amino acid residues linked via their side chains to each other.

11. The method or use of claim 10, wherein the linked amino acid residues are at positions 13 and 17 or at positions 26 and 30.

12. The method or use of Claim 11, wherein the amino acid residue at position 17 is an aspartic acid.

5 13. The method or use of Claim 12, wherein the PTHrP analogs are:

┌──────────────────┐  
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu  
Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr hSerlac (SEQ  
ID NO:5) or

10 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu  
Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub>  
(SEQ ID NO:6).

14. The method of any one of claims 1 or 3-6 or the use of claims 2 or  
15 anyone of claims 3-6, wherein the PTHrP analog is an N-terminal truncate of  
30 to 50 amino acid residues with optionally substituted at positions 5, 13, 17,  
19, 26, 30, 32 and/or 34.

15. The method or use of Claim 14, wherein the PTHrP analog is:

Ala Val Ser Glu Ile Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
20 Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
NO:7),

Ala Val Ser Glu Ile Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Ala  
Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr Ala NH<sub>2</sub> (SEQ ID  
NO:8),

25 Ala Val Ser Glu Ile Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Ala  
Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Pro NH<sub>2</sub> (SEQ ID NO:9),

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr D-Orn  
lactam (SEQ ID NO:10),

30 Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg  
Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr hSer lactam (SEQ  
ID NO:11) or

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser IleGln Asp Leu Arg  
Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu His Thr hSer Thr His Ile  
Gln NH<sub>2</sub> (SEQ ID NO 12).

1/6

# PTHrP Study - Defect

Figure 1




Figure 3A

Example of a high resolution radiograph of non-united defect at 6 weeks




Figure 3B

Example of a high resolution radiograph of a healed defect at 6 weeks






Figure 4A

Trabecular Bone of Femur




5/6



Union Rate at 6 Weeks

Figure 5





**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/29</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/12561</b> <b>(43) International Publication Date:</b> 18 March 1999 (18.03.99)
<b>(21) International Application Number:</b> PCT/EP98/05550 <b>(22) International Filing Date:</b> 2 September 1998 (02.09.98) <b>(30) Priority Data:</b> 60/058,324 9 September 1997 (09.09.97) US <b>(71) Applicant:</b> F. HOFFMAN-LA ROCHE AG [CH/CH]; 124 Grenzacherstrasse, CH-4070 Basel (CH). <b>(72) Inventor:</b> VICKERY, Brian, Henry; 27977 Via Ventana, Los Altos Hills, CA 94022 (US). <b>(74) Agent:</b> BRAUN, Axel; 124 Grenzacherstrasse, CH-4070 Basel (CH).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 14 May 1999 (14.05.99)
<b>(54) Title:</b> FRACTURE HEALING USING PTHrP ANALOGS  <b>(57) Abstract</b>  The present invention provides methods of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, wherein amino acid residues 22-31 form an amphipathic $\alpha$ -helix or the use of such a polypeptide for the preparation of a medicament for the treatment of bone healing and fracture repair.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Internatic Application No

PCT/EP 98/05550

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K38/29

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 02610 A (SYNTEX INC) 26 January 1995 see page 22, line 40 - page 23, line 2; claims ---	1-15
Y	WO 97 07815 A (SYNTEX INC) 6 March 1997 cited in the application see page 27, line 1 - line 7; claims ---	1-15
Y	WO 94 01460 A (SYNTEX INC) 20 January 1994 cited in the application see page 22, line 25 - line 30; claims ---	1-15
Y	WO 96 40775 A (SYNTEX INC) 19 December 1996 see page 21, line 28 - line 33; claims --- -/--	1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**Special categories of cited documents:**

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 February 1999

Date of mailing of the international search report

09/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

# INTERNATIONAL SEARCH REPORT

Internatic      Application No  
PCT/EP 98/05550

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 11697 A (CHUGAI PHARMACEUTICAL CO LTD ;MORI TAKASHI (JP); HIGASHI SAYUMI (J) 4 May 1995 cited in the application & DATABASE WPI Derwent Publications Ltd., London, GB; AN 95-178649 & WO 95 11697 A see abstract ---	1-15
P,Y	WO 98 30590 A (BIOMEASURE INC ;DONG ZHENG XIN (US)) 16 July 1998 see page 10, line 11 - line 16; claims ---	1-15
Y	WO 97 02834 A (BIOMEASURE INC ;DONG ZHENG XIN (US)) 30 January 1997 see page 11, line 6 - line 11; claims ---	1-15
Y	WO 94 02510 A (SANDOZ AG ;SANDOZ AG (DE); SANDOZ LTD (CH)) 3 February 1994 cited in the application see page 62, last paragraph - page 63, paragraph 1; claims ---	1-15
Y	WO 96 40193 A (BETH ISRAEL HOSPITAL) 19 December 1996 cited in the application see page 8, line 15 - line 19; claims -----	1-15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05550

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9502610 A	26-01-1995	AU 671851 B	12-09-1996
		AU 4670593 A	31-01-1994
		CN 1127000 A	17-07-1996
		EP 0651765 A	10-05-1995
		FI 950169 A	13-01-1995
		JP 7509228 T	12-10-1995
		NO 950140 A	13-01-1995
WO 9707815 A	06-03-1997	AU 6958996 A	19-03-1997
		CA 2230929 A	06-03-1997
		CN 1193915 A	23-09-1998
		EP 0858344 A	19-08-1998
WO 9401460 A	20-01-1994	US 5589452 A	31-12-1996
		AU 671851 B	12-09-1996
		AU 4670593 A	31-01-1994
		CA 2140281 A	20-01-1994
		EP 0651765 A	10-05-1995
		FI 950169 A	13-01-1995
		HU 69628 A	28-09-1995
		HU 9500281 A	28-09-1995
		JP 7509228 T	12-10-1995
		MX 9304226 A	31-01-1995
		NO 950140 A	13-01-1995
		NZ 254554 A	26-03-1996
		US 5693616 A	02-12-1997
		US 5695955 A	09-12-1997
		US 5807823 A	15-09-1998
		US 5840837 A	24-11-1998
		US 5798225 A	25-08-1998
		US 5821225 A	13-10-1998
WO 9640775 A	19-12-1996	US 5821225 A	13-10-1998
		AU 6251596 A	30-12-1996
		CA 2223832 A	19-12-1996
		EP 0835262 A	15-04-1998
WO 9511697 A	04-05-1995	AU 8002994 A	22-05-1995
		JP 7238033 A	12-09-1995
WO 9830590 A	16-07-1998	AU 5519998 A	03-08-1998
WO 9702834 A	30-01-1997	US 5723577 A	03-03-1998
		AU 6483496 A	10-02-1997
		CA 2226177 A	30-01-1997
		CN 1199340 A	18-11-1998
		EP 0847278 A	17-06-1998
		PL 325905 A	17-08-1998
WO 9402510 A	03-02-1994	SK 3198 A	08-07-1998
		AU 4156693 A	20-01-1994
		CA 2100423 A	16-01-1994
		CH 688195 A	13-06-1997
		CN 1099801 A	08-03-1995
		CZ 9500088 A	18-10-1995
		DE 4393381 T	27-04-1995
		EP 0672057 A	20-09-1995
		FI 950171 A	13-03-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 98/05550

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9402510 A		GB 2269176 A,B HU 70459 A HU 9500320 A IL 106326 A JP 6184198 A MX 9304251 A NO 950123 A NZ 248137 A SK 4395 A ZA 9305126 A	02-02-1994 30-10-1995 30-10-1995 30-09-1997 05-07-1994 28-02-1994 15-03-1995 21-12-1995 07-06-1995 16-01-1995
WO 9640193 A	19-12-1996	US 5717062 A EP 0772448 A JP 10512280 T	10-02-1998 14-05-1997 24-11-1998